Head-to-head · WeighScore
Spry vs Tryozi
The verdict
Tryozi takes it — 61.4/100 to 56.8/100.
Tryozi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Florida telehealth selling compounded GLP-1 injections at a flat price that does not rise with dose, naming all four of its 503A compounding pharmacies.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Spry | Tryozi |
|---|---|---|
| WeighScore | 56.8/100 | 61.4/100 |
| Grade | C | C |
| Scorecard rank | #409 | #296 |
| Semaglutide | $199/mo (starting dose, compounded) | $279/mo (compounded) |
| Tirzepatide | $299/mo (starting dose, compounded) | $379/mo (compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #409 · C
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
Where it loses points
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #296 · C
Strengths
- Names all four of its 503A compounding pharmacies: RedRock, Health Warehouse, Precision Medicine and Triad Rx
- Price does not increase as your dose increases, stated plainly on the pricing page
- Full total shown before payment, with the first-month discount and the ongoing rate both visible
- States plainly that compounded medications are not FDA-approved, a disclosure many competitors omit
- LegitScript certification verified against the issued seal, not just the badge
Where it loses points
- Headline $139 is a first-month half-price offer; the ongoing rate is $279
- Multi-week plans are billed once as a single upfront charge, not as a lower monthly rate
- Plans ship every 4 weeks, so a 52-week plan is 13 shipments rather than 12 months
- No refund policy detail is published on the pricing page itself
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.